Item
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Title (Dublin Core)
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Description (Dublin Core)
The new process of coronavirus vaccine in China
Beijing Institute of Biotechnology; NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention; China National Institute for Food and Drug Control; Hubei Provincial Center for Disease Control and Prevention; Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity; CanSino Biologics; Clinical Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Shanghai Canming Medical Technology
Date (Dublin Core)
Creator (Dublin Core)
Contributor (Dublin Core)
Type (Dublin Core)
Article
Link (Bibliographic Ontology)
Publisher (Dublin Core)
The Lancet
Controlled Vocabulary (Dublin Core)
Curator's Tags (Omeka Classic)
Collection (Dublin Core)
Date Submitted (Dublin Core)
05/25/2020
Date Modified (Dublin Core)
06/06/2020
1/27/2021
03/28/2021
Accrual Method (Dublin Core)
5083